CARB-X funds Immunethep to develop vaccine to prevent E.coli infections

Immunethep has been awarded $2 million in funding from CARB-X to support the development of our conjugated peptide-based vaccine against invasive Escherichia coli infections.

With no existing vaccine for E. coli, this funding will help Immunethep to advance its platform technology to induce robust and long-lasting immunity, addressing a critical unmet medical need. E. coli is a major cause of bloodstream infections, sepsis, meningitis, and other life-threatening conditions, particularly in vulnerable populations. The rise of antibiotic-resistant strains further underscores the urgency of developing effective preventive solutions.

We are grateful to CARB-X for their support and confidence in our innovative approach. Together, we are taking a significant step forward in the fight against E. coli infections and antimicrobial resistance.

Find out more at the CARB-X website. Link here